Protagonist Therapeutics, Inc (PTGX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$194.0M
Cash & Equivalents
$48.9M
Quarterly Burn Rate
12 mo
Est. Cash Runway
$6,573M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05210790 | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera | PHASE3 | Active Not Recruiting | 293 |
| NCT06033586 | Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera | PHASE3 | Active Not Recruiting | 46 |
| NCT07153146 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects. | PHASE1 | Recruiting | 142 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.